S
UI FASALAZINE lSALAZOPYRINE PHARmacia) (I) is an azo compo und compromised of two moieties; sulfapyridinc and 5-aminosalicyl ic acid ( 5-ASA) Sulfapyridine acts as the vehicle and ny ib binding with 5-ASA prevcnrs absorr· tion of 5-ASA in the small in testi ne The active part is 5-ASA, released by bacte· rial cleavage in the colon ( 2) . Sulfapyridinc is associated with most of the side effects associated with sulfasalazine (), 4) As of September 1986, there arc two preparations in Canada of 5-ASA available on the market: Asacol (Norwich Eaton) 400 mg cable ts, and Salofalk (imer· folk) 4 g enemas. Other preparations available for investigative and compas· sionate use include Salofalk. 2 50 mg tab· le ts; Rowasa (Reid-Rowell, USA), 250 mg tablets; Penrasa (Fcrring, Sweden), 250 mg tablets.ind Oipcncum (Pharma· cia), 2 50 mg tablets. Sn lofalk suppositories arc available in 2 50 and 500 mg size and Rowasa supposimries in 500 mg. Rowasa is also available as a 4 g cncm;,.
CAN J GASTROFNI I Rlll
Slow release oral prepararions include: Asacol, Salofalk, Rowasa and Penrnsa. Asacol is coated with Eud ragit-S, which enables the pill to be released above pH 7 in the colon , dissolution being slow at pH 2 to 6 and 4 to 8 h at a pH of7 .5.
Salofalk, which is coated with ethylcellulose plus Eudragit-L. is released at pH greater than 5.6 in the ileu m anJ is dissolved in I. 5 to 2 h ar pH 7. 5. Rowasa issimilarto Salofalk, while Pcntasa has an ethyl-cellu lose covering only and is s::iiJ to be available at any pH. It should, therefore, be of particuh1r use for treatment of Crohn's diseasc in the stomach and small intestine.
The 5-A SA oral preparations, which require colonic bacterial action for release of the active mo iety, include Salazopyrine, wh ich is 5-ASA and sulfopyridine; Oipentum, which is a dimer of two molecules of 5-ASA: and Po lyasa, which is a dimer of 5-ASA and sulfanilamidc ethylene polymer.
SIDE EFFECTS
The side effects of o ral p reparatio ns of 5-ASA arc infreque n t and dose related, with headache, n::iusca. epigasrric distress and diarrhea being the most common complaints. H owever, with salazopyrinc, side effects a rc mo re frequent, up to 30% ( 5), a re mainly dose re lated with occasio n al hyp e rsensitivity reaction s ll.4). The side effects include a norexia, nausea, vo mi tin g, ep iga str ic distress, rash and rare reactions such as agranulocytosis, aplastic o r he m olytic a nemia, pancreatitis. d rug-induced bloody diarrhea (6) and infertility (7, 8) being ascribed to hypersensitivity reactions.
Side effects of the rectal fo rms include occasiona l recta l sore ness and possible hair loss a nd the initial inability to retain the 5-ASA supposi to ries anJ enem as. There arc no readily available commercial preparatio ns of sulfasalazine for rectal use at the present time.
Con traindications to 5-ASA therapy include: severe renal disease; severe live r disease; active peptic ulce r; ;ind coagulopathies. Hypersensitivity re;ictions h;ive been rarely descri bed such as, drug rnsh . fever, bronchospasm and a lupus-like syndro me. Drug interactions arc th eoretica ll y possible wit h su lphanylurcas. coumari n s. methotrexacc. probenicid.
,.w----. w--.wspironolactonc. furosa mide and rifampin (manufac ture r's safety suggestions).
5-ASA USE
5-ASA 1s useful in inflammatory bowel disease. both ulcerative coli tis and Croh n's disease. Its use has been tested in the treatmen t o f acute flare-ups of ulcerative col itis as well as in maintenance therapy, and for acti ve C ro h n's disease.
ORAL PREPARATIONS
Ulcerative colitis: In a two-week clinica l trial (9) . l 3 of 20 patients given 2 g/ day Oipentum for active ulcerative coli tis improved, compared to e igh t of 20 p;itients given ;i placebo. O ne patient given Oipe ntum worsened compared to nine p;iticnts in the placebo group.
Salofalk ( 1.5 g/day) and sulfasalazi nc (3 g/day) were equally effective in controlli ng ulcerative colitis over eigh t weeks in 30 patients ( I 0) .
In an open trial of Polyasa ( 1.6 g/ J ,1y for six weeks) seven of LO patien ts cli nically improved ( l l l. No con trol data was available for treatmen t of u lccra ti vc colitis with Polyasa.
Oral 5-ASA (Asacol 1.2 g/d ay) was compared with Sa lazopyrine (2 to 3 g/d ay) in th e maintenance treatment of ulcerative colitis in 6 7 patients ( 12 ). Relapse at four months occu rred in nine of 34 (26%) taki ng Asacol a nd six of 33 ( 18%) raking sa lazopyrin e (no significa n t difference). In a later report ( 12), seven of 32 patients ( 22°i.) re lapsed a t six months on Asacol, 2. 7 g/day, compared to five of 2 5 (20<\) taking salazopyrine, 2 to 3 g/day.
ln another open trial ( 13 ), the effect of Asacol ;ilone. 2 g/dny. in patients with u lcerative colitis was compared with a   TABLE 1 5-ASA ,n inflammatory bowel disease second group of patien ts who were more sick and requ ired As;icol plus pred niso ne. 10 to 15 mg/day. There were 19 patients in the first group and 12 patients in the seco nd . Relapse occurred in two of 19 ( 10%) with Asacol, and in five of 12 ( 41 '\) wi th the d rug combina tion.
Crohn's disease: Penrnsa has been used nt ;i dose of I . 5 g/dny for IO days in 12 patients with active Crohn's dise;ise ( 14). There was no ch ange in the Croh n's dise;isc activi ty index (COAi ) versus pl ace bo. In another study using Pc nrnsa ;i t I . 5 g/day or six weeks in 18 pmicnts, rhe cl inical co nditio n of I 3 patie nts improved whi le three worsened. The COAi before treatmen t was 226 ( normal. less than 150) and fe ll to 99 after treatment ( 15). In a double-blind study of oral 5-ASA (Salofalk. I . 5 g/day ) vcrsussulfasalazinc ( 3 g/day). 13 of 15 patie nts taking 5-ASA and 12 of 15 patients caking sulfasalazine improved afte r eight weeks ( 10). In the group taking Salofalk . the C OAi before treatment was 308 .i. 72 falling to 11 9 +:-82, (P < 0.0001 ). In rhe group taking su lfasalazinc rhe C OAi before treatment was 310.L 75. dropping to 162 + 11 5 (P<0.000 I ) afte r trea tm ent.
RECTAL PREPARATIONS
Suppositories: S;ilofolk su ppositories ( 1.5 g/d ay) were used to rrcat 14 patients with ulcerative colitis anJ induced remission 111 l 2 (86",,) A te r six weeks' therapy. ln the same study using the parent compound, sulfasalazinc, only seven of 11 patients (64°10) achieved remission in the sa me time frame . This is contrasted with one of seven patients caking sulfapyridin c ( 14',) who ach ieved remission over the six-week treatment period ( 16). In Cnnad;i, a J,!rnup from 1-lalifo, and Toronto performed a double-hltnd, rrosrecllvl'. rnndom1zl·d. mult1centrl', placebo-concmlkd study oi 5-ASA m thl' treatment ot active dist;il rroctitis ( 17). Cncena tor entry mcluded patients \\1th 15 cm, or less. nf diffuse inflammation mvol\'mg the rt'Ctum. who were t·1ther unresponsive to standard therapy. hulf asaLrmt· or steroid! or nt•wly referred. u!Hrl'ated pant•nts. The adnrn,silin cri tcna included ,1 d1sea,e ,1ct1v1ty scorl' (DAI) of 1 ,ir greater involvmg at least two of f11ur catl'g(mes (T.1ble I). The minimum scordnormal l was 0, the ma,-1mum score was 12 Pauents were ambu latory, aged at least 18 vears, havmg had m, 4 ASA or 5-ASA w1thm rwn days beti,re entry and no recwl stl•roids withm two weeks hetorl' entry. 5-ASA surpos1 tones f 'il10 mg) or a placeh11 were used, rhrl't' llnlt's a dav, for six \\'Cl'ks. After six wnis. svmptomat1c panents \\'l're offered open act1Vl' 5-ASA If m rem1ss1nn , 5-ASA wasoffored to maintain rem1ss10n and other drugs withdrawn The m1111 mum dose of 5-ASA suppository to m,1int,1m remiss10n was sought Thcrt· ,, re t·1ghc mt'n and six w,,ml'll m dw ,Kll\'l' group and nll1l' men and !tiur wnmt•n in the placebn group, mt•an age of 37) + 14.5and42 7' 1 l.2years, respeCU\'l'ly One male m the placebo grou p drorped out at three weeks and another male in the placebo group had salmonelln ,ind was excluded. There was no s1gn1ficant J1fterence 111 tht· DAI between the two groups beforl' treatmt·11t 7 I ' I ~ acm-e \'l'rsus 7 4 t I ~ placebo woups (Tabll' 2) However. thl'rt' was a highly s1g111f1cant difference at rhret· weeks, arnve group DA I I 6 t I 5 pla echo group 5 ~ I 9 Thh did nor mcrea,l in s1gnifi.-ance at six \\'eeks, active group DAI 0.4 0.9. plan·ho grour 5 4 3 4. The placebo group ,core, \\'l'rl' not sig111f1Cantl) diffrrl'nt from rhc baseline valut' at three or six weeks.
Ther~· wa, an apparent se, difference in rl'spon,e .ill the males in thl' active group had heall'd rnmplett'h m , 1x \\'eeks, whereas thrct· tif the six wonwn had improved s1gnif11.antly hut were nut com· pktl'lv hl·aled In .1 concurrl'nt study 117 l. In a separate study of patients with soli tary ulcers of the rectum, symptoms disappeared completely when 5-ASA suppositories were given ( LS) The ulcers d isappeared on sigmo1doscopy and biopsies confirmed this rapid resolution of pathology ( Figures 2A and B) .
Salofalk suppositories induced and ma111tained rem1ss1011 in virtua lly all patients with actl\'C ulcerative proctitis hue only m 50'\, of pam·nts with rectal Crohn's disease ( 19) In the Canadian study ( 20} tht· rem1hl>ion rate using 5-ASA suppos1tortl'S alone was 18°., at 26 weeks. comparable w any other fo rm of treatment The m1111mum dn:;e necessary to ,Kh1eve remtss1on vaned from one supposit1,r), at night to one suppository every second or third rnght. Enemas: Sutherland :ind Martin (21) report that 5-ASA enemas, used 111 a prospt•cm·t· placebo-controlled study in 15 3 pa1ie11ts wnh ldt sided and distal -----~ ulcerative colit b. were highly effective There \\ as no difference between the number of patien ts, the sex rntin, the age. the \\'l'1ght and the dur:rnon of the disease in the active ;i nd placeho grour or m the percenwge of patients wuh thl' firs t episode. the baseline disease activ· icy sccm• in the males or females, or tht· use of concu rrent medication. However there were six "dropouts" m the 5-ASA group and 22 in thl' placebo group Thi~ was related t0 offering active medication to those who were not responding at three weeks. The physician rnu ng of "much irn proved" showed a significant difference for males who responded better than females w hen ench was compared to placebo. Twt 
